Interpace Biosciences (PF42) Stock Overview

Provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. More details

PF42 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 74.5% below our estimate of its fair value

Earnings grew by 285.4% over the past year

Risk Analysis

High level of non-cash earnings

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€61M)

PF42 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Interpace Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Interpace Biosciences
Historical stock prices
Current Share Price	US$1.68
52 Week High	US$1.68
52 Week Low	US$1.07
Beta	0.97
1 Month Change	21.74%
3 Month Change	57.01%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	57.01%

Recent updates

Shareholder Returns

	PF42	DE Healthcare	DE Market
7D	6.3%	-2.2%	0.5%
1Y	n/a	2.8%	8.5%

Return vs Industry: Insufficient data to determine how PF42 performed against the German Healthcare industry.

Return vs Market: Insufficient data to determine how PF42 performed against the German Market.

Price Volatility

Is PF42's price volatile compared to industry and market?
PF42 volatility
PF42 Average Weekly Movement	4.3%
Healthcare Industry Average Movement	6.5%
Market Average Movement	6.0%
10% most volatile stocks in DE Market	14.3%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: PF42 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine PF42's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	102	Tom Burnell	www.interpace.com

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer.

Interpace Biosciences, Inc. Fundamentals Summary

How do Interpace Biosciences's earnings and revenue compare to its market cap?
PF42 fundamental statistics
Market cap	€51.73m
Earnings (TTM)	€21.21m
Revenue (TTM)	€32.87m

2.4x

P/E Ratio

1.6x

P/S Ratio

Is PF42 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PF42 income statement (TTM)
Revenue	US$38.73m
Cost of Revenue	US$14.60m
Gross Profit	US$24.13m
Other Expenses	-US$854.00k
Earnings	US$24.98m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.90
Gross Margin	62.31%
Net Profit Margin	64.51%
Debt/Equity Ratio	0%

How did PF42 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/16 00:57
End of Day Share Price	2026/04/16 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Interpace Biosciences, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Benjamin Haynor	Alliance Global Partners
Paul Knight	Brean Capital Historical (Janney Montgomery)
Raghuram Selvaraju	H.C. Wainwright & Co.

Interpace Biosciences, Inc.MUN:PF42 Stock Report